CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target
source. Convection-Enhanced Delivery (CED) is a method of direct infusion of drugs under
controlled pressure to the tumor that may reduce systemic side effects of drugs in the
patient.
The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a
water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely
in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study
will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor
over 9-11 days.